Overview

Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Status:
Unknown status

Trial end date:
2018-03-01

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well giving abiraterone acetate and prednisone with or without dasatinib works in treating patients with metastatic, hormone-resistant prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as abiraterone acetate, may lessen the amount of androgens made by the body. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether abiraterone acetate and prednisone is more effective than abiraterone acetate, prednisone, and dasatinib in treating prostate cancer

Phase:

Phase 2

Details

Lead Sponsor:

University of Southern California

Collaborator:

National Cancer Institute (NCI)

Treatments:

Abiraterone Acetate
Dasatinib
Prednisone